To elucidate the effects of insulin-like growth factor I (IGF-I) on fuel oxidation and insulin sensitivity, eight healthy subjects were treated with saline and recombinant human IGF-I (10 ;tg/kg * h) during 5 d in a crossover, randomized fashion, while receiving an isocaloric diet (30 kcal/kg-d) throughout the study period. On the third and fourth treatment days, respectively, an L-arginine stimulation test and an intravenous glucose tolerance test were performed. A euglycemic, hyperinsulinemic clamp combined with indirect calorimetry and a glucose tracer infusion were performed on the fifth treatment day. IGF-I treatment led to reduced fasting and stimulated (glucose and/ or L-arginine) insulin and growth hormone secretion. Basal and stimulated glucagon secretion remained unchanged. Intravenous glucose tolerance was unaltered despite reduced insulin secretion. Resting energy expenditure and lipid oxidation were both elevated, while protein oxidation was reduced, and glucose turnover rates were unaltered on the fifth treatment day with IGF-I as compared to the control period. Enhanced lipolysis was reflected by elevated circulating free fatty acids. Moreover, insulin-stimulated oxidative and nonoxidative glucose disposal (i.e., insulin sensitivity) were enhanced during IGF-I treatment. Thus, IGF-I treatment leads to marked changes in lipid and protein oxidation, whereas, at the dose used, carbohydrate metabolism remains unaltered in the face of reduced insulin levels and enhanced insulin sensitivity. (J. Clin. Invest. 1993. 92:2249-2256
Introduction
Growth hormone (GH)' stimulates hepatic synthesis and secretion ofinsulin-like growth factor-I (IGF-I) ( 1 ), which mediThis work was presented in part at the 53rd Annual Meeting of the American Diabetes Association, Las Vegas, NV, 12-15 June 1993.
1. Abbreviations used in this paper: AUC, areas under the curve; C-peptide, connecting peptide; CV, coefficient of variation; EE, energy expenditure; FFM, free fat mass; GH, growth hormone; Ra, rate of glucose appearance; Rd, rate of glucose disposal.
ates most of the growth-promoting activity of GH (2, 3) . In GH-deficient rodents (3) (4) (5) and in GH-insensitive Laron-type dwarfism, (6) IGF-I administration has growth-promoting properties.
Apart from its role as mediator of GH, IGF-I posesses insulin-like activity in vitro (7, 8) and in vivo (9) (10) (11) (12) . In normal rats, intravenously administered IGF-I results in hypoglycemia (9) . Intravenous (i.v.) bolus injections of IGF-I in humans rapidly induce hypoglycemia, similarly to insulin (10) . The effects of IGF-I infusion on glucose turnover, circulating FFA, and amino acids under euglycemic clamp conditions in humans are comparable to those of insulin (1 1, 12) .
However, divergent effects of insulin and IGF-I have been described in fasted rats (13) and pancreatectomized diabetic dogs ( 14) . Differences between the effects ofIGF-I and ofinsulin may be due to (a) the tissue distribution of their respective receptors and (b) the IGF-I specific inhibition of growth hormone and insulin secretion (15) (16) (17) (18) . Whereas skeletal muscle tissue has type I IGF as well as insulin receptors (7), other target cells of insulin such as adipocytes ( 19) and hepatocytes (20) have few, if any, functional type I IGF receptors. In these latter tissues, the biological effects of IGF-I are due to crossreaction of IGF-I with the insulin receptor. Because the affinity of IGF-I to the insulin receptor is only 1% of that of insulin ( 19) , only large doses of IGF-I affect lipolysis and hepatic glucose production. IGF-I administration in healthy humans is followed by a dose-dependent reduction of insulin and GH secretion. At the same time, fasting glucose levels and glucose tolerance remain unchanged suggestive ofincreased insulin sensitivity, either directly and/or indirectly via reduced insulin and GH levels, during administration of 18) .
Although the insulin-like effects of IGF Finally, a euglycemic, hyperinsulinemic clamp, combined with the isotope dilution technique and indirect calorimetry was performed on day 5 (Fig. 1 b) penditure were measured by indirect calorimetry using a computerized, flowthrough canopy gas analyzer system (Deltatrac; Datex, Helsinki, Finland). To determine urinary urea and uric acid excretion, and creatinine clearance, 24-h urine samples were collected from day 4 to day 5. Urine was also collected on day 5 during the clamp study for calculations of protein oxidation during indirect calorimetry. Fat free mass (FFM) was measured on day S using the bioimpedance method (22) . Analytical determinations. Plasma glucose was measured immediately after blood sampling using an automated glucose-oxidase method (Glucose Analyzer 2, Beckman Instruments, Inc., Fullerton, CA). Blood samples for glucagon were collected in special tubes (lithium heparin 143 IU/ 10 ml and aprotinin 4000 IU/ 10 ml; Bayer, ZUrich, Switzerland), centrifuged immediately during 15 min at 1,550 g at 40C, and the supernatant was frozen at -20'C until analysis. Insulin, C-peptide, and GH levels were measured in serum (18) with commercially available RIA kits (Medipro AG, Teufen, Switzerland). Lower detection limits were 36 pmol/liter for insulin, 70 pmol/liter for Cpeptide, and 0.18 ng/ml for GH. For statistical analysis, 0 levels were assigned to the lower detection limit of the corresponding assay. Interassay coefficients of variation (CV) were 6.5% and 8.0% (100 and 480 pmol/liter) for insulin, 4.5% and 3.4% (470 and 1500 pmol/liter) for C-peptide, and 5.0% (730 ng/liter) for GH, respectively. The glucagon RIA was performed according to Christofides (23). Interassay CV were 12.6% and 10.8% (4.5 and 33 pmol/liter).
Total IGF-I levels in serum were measured by RIA according to a modification of a previously described method (24) . 250 M1 of serum was extracted through Sep-Pack cartridges (Waters Associates, Mil- Ail of IGF-I antiserum diluted 1:1,000, and 100 Ml of '251I-IGF-I were incubated for 24 h at 4°C. Antibody-bound radioactivity was precipitated with 40Mgg of rabbit gamma globulin and 50 Ml ofgoat anti-rabbit gamma globulin, diluted 1:7. Interassay and intraassay CV were 15.8% and 10.5%, respectively.
FFA were determined colorimetrically with a commercial kit (Wako Chemicals, Neuss, FRG) with an interassay CV of 6.7%. Tritiated glucose activity was determined after deproteinizing plasma with 0.3 mmol/liter Ba(OH)2 and 0.3 mmol/liter ZnSO4. Subsequently the supernatant was evaporated under vacuum. The pellet was resuspended in distilled water, supplemented with 5 ml of Aqualuma Plus (Lumac, Shaesburg, The Netherlands), and counted for 3 h in a liquid scintillation counter.
Determinations of serum urea, creatinine, uric acid, sodium, and potassium were performed in an auto-analyzer (model 747 Hitachi, Zurich). Creatinine clearance was calculated from serum and urine creatinine levels as in the Geigy Scientific Charts (25) .
All samples (except routine chemistry) were analyzed in triplicate (tritiated glucose activity) or duplicate (all other) in one assay in one or two dilutions. Care was taken to examine samples from the same individual in the same assay.
Calculations. Rates of glucose disposal (Rd) and glucose appearance (Ra) were estimated according to the non-steady-state equations of Steele as modified by deBodo et al. (26) . A pool fraction of0.65 and a distribution volume of 220 ml/liter for glucose were assumed. Hepatic glucose output was calculated by subtracting the rate of exogenously infused glucose necessary to maintain euglycemia (M-value) from the isotopically determined overall Ra. In calculating nonprotein energy expenditure (EE), the gaseous exchange attributable to protein oxidation was subtracted from total gaseous exchange under the assumption that for each gram of nitrogen excreted in urine, 5.95 liters of 02 was consumed, and 4.97 liters of CO2 was produced. The protein oxidation rate was estimated from urinary nitrogen excretion ( 1 g nitrogen = 6.25 g protein). Urinary nitrogen excretion was estimated on the assumption that 90% ofthe nitrogen appeared as urea. The proportion of nonprotein energy derived from fat and carbohydrate oxidation was calculated from the nonprotein respiratory quotient as previously described (27) . During insulin infusion negative rates of hepatic glucose output were calculated in all subjects. Such underestimations of Ra are mainly accounted for by a model error (28) . Since the M-value exceeded the isotopically determined glucose disposal during hyperinsulinemia, net nonoxidative glucose disposal (Rd [ nonox] ) was calculated by subtracting oxidative glucose disposal (Rd[ ox]) from the Mvalue. Energy expenditure is given in kilocalories per kilogram of FFM per day (see Fig. 6 ). Glucose turnover data are given in milligrams per kilogram ofbody weight per minute (see Table II ). Substrate oxidation rates are given in both units (see Fig. 6 Basal values. Plasma glucose, circulating insulin, and Cpeptide levels were within normal limits before the start of the infusions and remained unaltered during the control infusions with 0.9% saline (Fig. 2) . Total IGF-I levels were within normal values during the control period (24.1±6.7) and rose to 101.1± 1+8.5 nmol/liter after 24 h of IGF-I treatment and remained at that level thereafter (P < 0.01 ). Fasting plasma glucose levels decreased from 4.7±0.3 to 4.3±0.3 mmol/liter (P < 0.04) on the third IGF-I treatment day remaining stable thereafter (4.2±0.4 mmol/liter on day 5, P < 0.01 vs. control; Fig. 2 ). Insulin and C-peptide levels, initially 68.6±14.0 and 557.5±122.1 pmol/liter, decreased significantly on the second day to 37.9±4.1 (P < 0.01) and 216.6±57.2 pmol/liter (P < 0.01 ), respectively, and remained suppressed (Fig. 2) . Similarly, GH levels were suppressed to below the detection limit of the RIA during IGF-I treatment from the third day onward (P < 0.02; Fig. 2) .
Serum sodium and potassium remained unchanged during both treatment periods (not shown). Serum urea, uric acid, and creatinine levels remained unaltered during saline and decreased significantly during IGF-I treatment (Fig. 2) . This was accompanied by an increase of creatinine clearance and a fall ofurinary urea excretion on days 4-5 ofIGF-I treatment, while uric acid excretion remained unchanged (Table I) . L-Arginine stimulation test. During IGF-I treatment AUC of insulin, C-peptide, and GH were significantly decreased to 60±12% (P < 0.01), 59±24% (P < 0.01), and 12±91% (P < 0.03) ofcontrol, respectively (Fig. 3) . Basal values and AUC ofstimulated glucagon were unchanged (91±24%; NS), respectively as compared to those measured under saline treatment. Insulin, GH, and glucagon secretion upon arginine stimulation were, however, not delayed by IGF-I treatment.
Intravenous glucose tolerance test. Glucose tolerance was unaltered during IGF-I treatment despite concomitantly reduced insulin levels (Fig. 4) . AUC of insulin and C-peptide during the i.v. glucose tolerance test under IGF-I treatment were 65±14% and 53±10% of control (P < 0.01 for both), respectively. However, the insulin response to the intravenous glucose load was prompt and not delayed during IGF-I treatment.
Basal circulating FFA levels on day 5 ( Agg/kg h s.c., *) treatment in eight healthy subjects (mean±SD; * P <0.01, #P < 0.02).
Indirect calorimetry and euglycemic clamp. EE (Fig. 6 ) was markedly elevated in all subjects during IGF-I administration (i.e., 33 Figure 6 . Individual values and mean±SD of resting EE and lipid (L), carbohydrate (CH), and protein (P) oxidation (in kcal/FFM -d) on day 5 of saline and rhIGF-I (10 IOg/kg-h s.c.) treatment in eight healthy subjects (*P < 0.01, #P < 0.02).
and GH secretion ( 16, 18, and Fig. 2 ) that may be responsible for some of the findings in this study and may also account for some ofthe discrepancies between this and previously reported studies using acute infusions of IGF-I. During IGF-I treatment glucose tolerance did not change despite partial suppression of insulin and GH secretion ( 16, 18) . The present report extends these findings by showing that, although IGF-I reduces basal and stimulated insulin secretion, the reaction of the # cell to stimuli (arginine and glucose) remains prompt and not delayed. Similar results have been observed in hyperglycemic clamping under acute IGF-I infusions (30) . In contrast to a previous study (18) , we found slightly but significantly decreased fasting glucose levels under IGF-I treatment. A higher dose of IGF-I in a GH-insensitive (Laron) dwarf caused hypoglycemia and impaired glucose tolerance (31 ). The IGF-I dose used in the present study was sufficient to lower fasting glucose, probably via increased insulin sensitivity and/or diminished GH secretion while insulin secretion remained prompt and sufficient enough to keep glucose toler- (32, 33) . In addition, the reduction of GH levels in acromegalics is accompanied by improved glucose tolerance and sensitivity to insulin (34, 35). The reduction ofGH levels during IGF-I treatment may also have contributed to the enhanced insulin sensitivity. In preliminary experiments we have observed that the simultaneous treatment ofGH-deficient subjects with IGF-I together with GH is accompanied by few changes in tissue sensitivity to insulin, supporting the idea that the suppression of GH secretion plays a major role in the effects of IGF-I on glucose metabolism (M. A. Hussain, manuscript in preparation).
Glucose levels may have remained normal despite decreased insulin levels probably by an increase in insulin sensitivity and/or concerted glucose-lowering effects of IGF-I and insulin on skeletal muscle via their respective receptors (30) . In contrast, lipolysis may have remained unopposed due to a lack offunctional IGF-I receptors on adipocytes ( 19) and low circulating insulin levels. Inability of IGF-I to suppress FFA levels has previously been reported in rats (9, 13) . The ensuing rise in circulating FFA delivered the substrate for the elevated lipid oxidation shown in this study. We have no data at present on circulating ketone bodies during IGF-I therapy. However, marked ketogenesis has been reported in a case of a Laron dwarfwho received large amounts ofrhIGF-I leading to fasting hypoglycemia (31 ). The unchanged basal and stimulated glucagon levels in the face of reduced insulin levels may also have contributed to enhanced ketogenesis (36) . It appears that elevated levels ofIGF-I during a period ofseveral days do not alter the glucagon response to arginine (Fig. 3) . These data confirm results obtained with the perfused rat pancreas ( 17) . However, using an entirely different study design, Kerr et al. (37) have reported a somewhat diminished glucagon response to IGF-Iinduced hypoglycemia as compared to acute insulin-induced hypoglycemia. These apparent discrepancies are likely to be due to the different stimuli of glucagon secretion and maybe also to the higher and acutely administered IGF-I doses used by Kerr et al. (37) .
The elevation ofcirculating FFA was not accompanied by a substantial reduction in glucose metabolism. Nonetheless, the slight but statistically not significant reduction in oxidative and nonoxidative glucose disposal during IGF-I therapy may be explained by substrate competition (Randle cycle). Whereas insulin is relatively inefficient in counteracting lipolysis in acromegalics and in normal subjects receiving GH infusions (34, 38), circulating FFA levels were readily suppressed by exogenous insulin infusion in our subjects during IGF-I treatment. Moreover, this insulin effect was more pronounced during IGF-I administration than in the control phase with saline, possibly due to reduced basal insulin and GH secretion and consequently enhanced sensitivity of adipose tissue to insulin.
IGF-I administration also reduced protein oxidation as a reflection of a decrease in protein breakdown (11) (12) (13) 39) .
Studies in adult rats ( 13) and growing lambs (39) demonstrate that IGF-I inhibits protein breakdown. Inhibition of proteolysis by IGF-I has also been reported during acute IGF-I infusion and euglycemic clamping in humans (11, 12) . However, in these latter studies much larger doses of IGF-I were acutely infused such that cross-reaction ofIGF-I with insulin receptors could not be excluded by the investigators. All effects of the infused IGF-I mimicked those of insulin and glucose metabolism was stimulated. In contrast, basal glucose metabolism remained unchanged after 5 d of IGF-I administration in the present study, whereas protein oxdidation was clearly reduced, suggesting that all the effects observed with the smaller, nonhypoglycemic doses of IGF-I are mediated by the type I IGF receptor. Anticatabolic effects of IGF-I have also been demonstrated during dietary restriction in rats (40) and humans (41) .
In the present study we find consistent protein-sparing effects in healthy subjects also while on a controlled isocaloric diet. Most of the increase in EE during IGF-I treatment may be accounted for by increased net fat oxidation since more FFA (and presumably ketone bodies) are available. Increased glucose turnover, as found in acromegalics (42) , can be dismissed as a possible explanation for elevated EE because of the unchanged basal hepatic glucose production under IGF-I treatment. The conversion of thyroxine to triiodothyronine is enhanced under the influence of IGF-I at lower TSH levels (M. Hussain, preliminary observation) which might be responsible for enhanced EE, thermogenesis, and increased heat dissipation (43) . Some of the extra EE is required for the increased work load of the heart. A 10% rise of pulse rate and unchanged blood pressure values, as found in our subjects under IGF-I treatment, only leads to a 1-2% rise in the basal metabolic rate (44) . Thus, the elevated cardiac work by no means explains the elevated EE in the present study.
Most of the circulating IGF-I is noncovalently bound to specific binding proteins (IGFBPs). 80% of the IGF circulates in the form ofa heterotrimer together with an IGFBP-3 subunit and an acid-labile subunit. The serum levels ofthis complex is dependent on GH secretion. IGF-I therapy in the doses used in this study lead to an altered IGFBP profile with an elevation of IGFBP-l and -2 levels (45). Unbound IGF-I and IGF-I associated to IGFBP-I and 2 can cross the capillary barrier and reach target tissues (46). Therefore, a change of the IGFBP profile may also have contributed to the metabolic effects observed in this study.
IGF-I is considered to be the mediator of growth-promot- (52) and the induction of even higher IGF-I levels which may stimulate protein synthesis (39, 52) . Anabolism seems to be at its highest efficiency when GH, IGF-I, and insulin act in concert (52) . Among these hormones, insulin seems to be the only one that physiologically stimulates lipogenesis, whereas GH and IGF-I (at nonhypoglycemic lev-2254 els) allow the mobilization of caloric reserves from adipose tissue, albeit by different mechanisms. Our data reveal differences between the effects ofIGF-I and of those which have previously been shown of GH and insulin and may help understand the roles of these hormones in growth and metabolic homeostasis. Moreover, IGF-I may be a promising therapeutic agent in catabolic states without the adverse insulin antagonistic actions of GH and in situations where GH is ineffective (53) .
